I de kontrollerede og åbne kliniske studier blev der i forbindelse med tocilizumab indberettet klinisk signifikante hypersensitivitetsreaktioner, som krævede afbrydelse af behandlingen, hos 13 ud af 3778 patienter (0, 3%).
Clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation were reported in a total of 13 out of 3,778 patients (0.3%) treated with tocilizumab during the controlled and open label clinical studies.